M&A / Deals Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 Billion pharminent May 4, 2026
Clinical Data Celcuity strengthens case for ASCO-spotlighted breast cancer drug pharminent May 4, 2026
Other 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease pharminent May 4, 2026
Manufacturing PCI adds US sterile fill/finish capabilities through $1B global expansion drive pharminent May 4, 2026
Regulatory First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial pharminent May 4, 2026
Clinical Data Summit shares descend as PD-1/VEGF asset misses early survival mark pharminent May 4, 2026
M&A / Deals UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases pharminent May 4, 2026
Manufacturing Novartis unveils North Carolina API plant as final piece of $23B US expansion pharminent May 1, 2026
Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation pharminent May 1, 2026
Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualified Medicare Beneficiaries (QMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualifying Individuals (QIs) pharminent April 30, 2026
Policy / Pricing Average Drug Fills and Average Gross Drug Costs Per Medicare Part D Enrollee pharminent April 30, 2026
Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy pharminent April 30, 2026
Commercial Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch pharminent April 30, 2026
Commercial Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth pharminent April 30, 2026
Pipeline AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio pharminent April 30, 2026
Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints pharminent April 30, 2026
Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial pharminent April 30, 2026